IVD Medical Holding Full Year 2024 Earnings: EPS: CN¥0.17 (vs CN¥0.18 in FY 2023)

Simply Wall St

May 06, 2025

IVD Medical Holding (HKG:1931) Full Year 2024 Results

Key Financial Results

Revenue: CN¥3.16b (up 2.4% from FY 2023).
Net income: CN¥260.4m (up 9.3% from FY 2023).
Profit margin: 8.2% (up from 7.7% in FY 2023). The increase in margin was driven by higher revenue.
EPS: CN¥0.17.

Our free stock report includes 1 warning sign investors should be aware of before investing in IVD Medical Holding. Read for free now.

revenue-and-expenses-breakdown — SEHK:1931 Revenue and Expenses Breakdown May 6th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

The primary driver behind last 12 months revenue was the Distribution Business segment contributing a total revenue of CN¥2.95b (93% of total revenue). Notably, cost of sales worth CN¥2.41b amounted to 76% of total revenue thereby underscoring the impact on earnings. The most substantial expense, totaling CN¥183.8m were related to Non-Operating costs. This indicates that a significant portion of the company's costs is related to non-core activities. Explore how 1931's revenue and expenses shape its earnings.

IVD Medical Holding shares are down 4.0% from a week ago.

Risk Analysis

We don't want to rain on the parade too much, but we did also find 1 warning sign for IVD Medical Holding that you need to be mindful of.

New: AI Stock Screener & Alerts

Our new AI Stock Screener scans the market every day to uncover opportunities.

• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies

Or build your own from over 50 metrics.

Explore Now for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.